Square Pharmaceuticals PLC

Corporate Overview

Square Pharmaceuticals PLC is the flagship enterprise of Square Group and the undisputed market leader in Bangladesh’s domestic pharmaceutical industry since 1985. Listed on the Dhaka Stock Exchange under the ticker SQURPHARMA, the company commands approximately 17% of the total domestic prescription medicine market.

Founded in 1958 by Samson H. Chowdhury and three entrepreneurial partners in Pabna, the company has transformed into a globally compliant pharmaceutical multinational, operating advanced manufacturing sites in Gazipur and Pabna, alongside an overseas manufacturing subsidiary in Nairobi, Kenya.

Manufacturing Footprint & Regulatory Approvals

Square Pharmaceuticals maintains world-class formulation complexes certified by strict global regulatory authorities:

1. US FDA Approved Facilities: Manufacturing solid dosage forms complying with US 21 CFR standards for direct supply to the American prescription market.
2. UK MHRA & EMA Compliance: State-of-the-art sterile injectable, cephalosporin, and metered-dose inhaler (MDI) production suites supplying European healthcare authorities.
3. Active Pharmaceutical Ingredient (API) Plant: Integrated chemical synthesis plants located within the Munshiganj API Industrial Park to substitute raw material imports.

Market Leadership & Export Growth

Square exports over 900 formulation registrations across 45+ international markets in Europe, North America, Southeast Asia, and Africa. Supported by a 12,000+ strong national distribution force, Square ensures cold-chain and temperature-controlled medicine delivery across more than 100,000 retail pharmacies in Bangladesh daily.